Bulevirtide (chronic hepatitis D) – Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Bulevirtide (chronic hepatitis D) – Benefit assessment according to §35a Social Code Book V

   published on

   01.12.2025

   Document type

   PDF document, 651 kB, EN, not accessible

   DOI-Link

   https://doi.org/10.60584/A25-113_en

   Download file : Extract of dossier assessment (PDF document, 651 kB, EN, not accessible)
2. Dossier assessment

   Bulevirtide (chronic hepatitis D) – Benefit assessment according to §35a Social Code Book V

   published on

   01.12.2025

   Document type

   PDF document, 848 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/A25-113

   Download file : Dossier assessment (PDF document, 848 kB, DE, not accessible)

Dossier assessment

Project details

Project no.

A25-113

Commission

Commission awarded on 01.09.2025 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Immune system and infections

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-113_en

Connected Projects

1. Dossier assessment

   Bulevirtide (chronic hepatitis D, children ≥ 3 to < 18 years, ≥ 10 kg) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V

   Project no.

   G25-02

   Last updated

   01.04.2025

   Status: Commission completed

2. Dossier assessment

   Bulevirtide (chronic hepatitis delta virus infection) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

   Project no.

   G20-19

   Last updated

   01.12.2020

   Status: Commission completed